Mdd Us Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MDD US, and what generic alternatives to MDD US drugs are available?
MDD US has two approved drugs.
There are three US patents protecting MDD US drugs.
There are eighty patent family members on MDD US drugs in thirty-one countries and eleven supplementary protection certificates in ten countries.
Drugs and US Patents for Mdd Us
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-002 | Mar 21, 2017 | RX | Yes | Yes | 8,283,380 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Mdd Us | APOKYN | apomorphine hydrochloride | INJECTABLE;SUBCUTANEOUS | 021264-001 | Apr 20, 2004 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-002 | Mar 21, 2017 | RX | Yes | Yes | 8,076,515 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-001 | Mar 21, 2017 | RX | Yes | No | 8,076,515 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Mdd Us | XADAGO | safinamide mesylate | TABLET;ORAL | 207145-001 | Mar 21, 2017 | RX | Yes | No | 8,278,485 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Mdd Us Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Israel | 195294 | ⤷ Try a Trial |
Norway | 335537 | ⤷ Try a Trial |
Lithuania | 2474521 | ⤷ Try a Trial |
Taiwan | 201313662 | ⤷ Try a Trial |
Cyprus | 1109295 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Mdd Us Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1613296 | 15C0054 | France | ⤷ Try a Trial | PRODUCT NAME: SAFINAMIDE; REGISTRATION NO/DATE: EU/1/14/984 20150224 |
1613296 | C20150033 00258 | Estonia | ⤷ Try a Trial | PRODUCT NAME: SAFINAMIID;REG NO/DATE: EU/1/14/984 26.02.2015 |
1613296 | C 2015 034 | Romania | ⤷ Try a Trial | PRODUCT NAME: SAFINAMIDA; NATIONAL AUTHORISATION NUMBER: EU/1/14/984; DATE OF NATIONAL AUTHORISATION: 20150224; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/984; DATE OF FIRST AUTHORISATION IN EEA: 20150224 |
1613296 | CA 2015 00042 | Denmark | ⤷ Try a Trial | PRODUCT NAME: KOMBINATION AF SAFINAMID OG LEVOPODA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150224 |
1613296 | 122015000058 | Germany | ⤷ Try a Trial | PRODUCT NAME: XADAGO; REGISTRATION NO/DATE: EU/1/14/984 20150224 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.